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Abstract
Purpose There are no data regarding the actual need for
fertility preservation (FP) in breast cancer (BC) patients.
Our study provides a practical needs assessment for
reproductive medicine by analyzing an unselected cohort
of young BC patients. This assessment considers onco-
logical factors as well as the patient’s obstetrical and
gynecological history and reproductive outcome after BC
diagnosis. We aimed to identify how many patients are
actually potential candidates for FP and how many patients
might consequently use their cryopreserved gametes to
achieve pregnancy.
Methods Based on a prospective BC database, we ana-
lyzed all patients who were B40 years at initial diagnosis
(time period of diagnosis: 1990–2007; n = 100; 7.7 % of
the entire BC cohort; median age: 35.9 years).
Results Using an algorithm of exclusion criteria consid-
ering disease-specific, therapy-specific and family history
characteristics, 36 patients who received chemotherapy
were identified as potential ‘‘classical’’ candidates for FP.
After 5 years, 22 women were identified as potential can-
didates for using their cryopreserved gametes to achieve
pregnancy; the majority of these patients were childless
(n = 16, 72.7 %) and in their late reproductive years
(n = 12, 54.5 %).
Conclusions Our study demonstrates that in a cohort of
young BC patients only a minority of women are candi-
dates for FP. Young BC patients who wish to have children
in the future usually carry risk factors both from onco-
logical and reproductive medicine perspective. Due to this
high-risk profile, the rarity of BC in young age and the
limited number of patients who might actually have opted
for FP, these women must be offered timely and multi-
disciplinary counseling in highly specialized centers.
Keywords Breast cancer  Fertility preservation 
Oncofertility  Chemotherapy  Endocrine therapy
Introduction
In 2012, an estimated 1 in 200 women under the age of 40
will develop invasive breast cancer (BC). Invasive BC is the
most frequent cancer of young women and the leading cancer
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causing death in the age group between 20 and 39 years [1].
Women under 40 comprise about 5 % of the overall BC
population [2]; many of them have not completed child-
bearing at the time of BC diagnosis. In 2009, birth rates
declined for all women in the age groups from 15 to 39 years,
but continued to rise for women aged 40–44 and remained
unchanged among women aged 45 and older [3]. Consider-
ing the trend toward postponing child bearing to the late
reproductive years, the number of childless women at diag-
nosis of BC will continue to increase. In a recent US survey
77 % of childless women intended to have a child in the
future [4]. In another survey, 75 % of young cancer survivors
without children stated they wanted to have children in the
future and almost a third of the survivors who already had at
least one child wanted to have another child [5].
Mortality rates for BC patients are decreasing but BC
treatment will render many of the affected women infertile.
Particularly women without children are distressed about
their impaired family planning perspectives [6]. Therefore,
fertility after BC treatment and preservation of fertility at
diagnosis are issues that are currently receiving significant
attention. The American Society of Clinical Oncology
(ASCO) and the American Society for Reproductive
Medicine (ASRM) have recommended that the impact of
cancer treatments on fertility should be addressed with all
cancer patients of reproductive age and that options for
fertility preservation (FP), such as embryo cryopreserva-
tion, should be discussed routinely [7, 8]. Large cancer
centers have followed these recommendations and today
many cancer patients have access to reproductive medi-
cine. According to registries of fertility centers performing
FP consultations and treatments in Europe and the US, the
largest group of young women counseled for cancer ther-
apy-related FP were patients with BC, followed by women
diagnosed with a lymphoma [9]. There are, however, no
data regarding the actual need for FP consultations and
treatments in young BC patients. To our knowledge, this
study is the first to provide an assessment of the practical
necessities in family planning and FP by analyzing an
unselected cohort of young BC patients. This assessment
considers oncological factors such as disease stage, onco-
logical therapies and outcome as well as the patient’s
obstetrical and gynecological history and reproductive
outcome after BC diagnosis. The aim of this study was to
identify how many patients are actually potential candi-
dates for FP and how many patients might consequently
use their cryopreserved gametes to achieve pregnancy.
Patients and methods
The prospective relational web-based Basel Breast Cancer
Database (BBCD) includes all newly diagnosed primary
invasive BC cases treated at the University Women’s
Hospital Basel, Switzerland, since 1990. This institution
comprises the largest breast center in the canton of Basel
and represents the population of the region. In the BBCD
disease-specific clinical, histo- and pathomorphologic fea-
tures and treatment characteristics are collected. It also
includes data regarding personal and family history and
outcome. The data were recorded continuously from the
medical files.
A standard patient history included the basic obstetrical
information (such as parity, number and age of delivered
children, age at live births, etc.) and gynecological data
(such as, age at menarche, time of the last menstruation for
pre-/perimenopausal women, menopausal state and age at
last menstruation for postmenopausal women). Further-
more, a history of hysterectomy, bilateral oophorectomy,
endocrine treatment (e.g., hormonal replacement therapy,
use of contraceptives and other systemic or local hormonal
treatments) and current method of contraception (including
history of tubal ligation or vasectomy of the partner) was
recorded.
For this study, we analyzed all patients who were
diagnosed with invasive BC between 1990 and 2007 and
who were 40 years or younger at initial diagnosis
(n = 100, 7.7 % of all patients with newly diagnosed BC
in the above mentioned period). We had complete data
regarding postoperative BC therapy and follow-up in 97 of
these patients (three patients were lost to follow-
up B3 months after BC surgery). All cases were followed
until death or, if they remained alive, for a maximum of
21 years. The median follow-up duration after BC diag-
nosis was 99 months (range \1–252 months). At the time
of data collection in January 2012, the outcome data of
patients still alive were not older than 3 months.
Patients diagnosed between 1990 and 2007 were
routinely informed by the oncologist about the possible
gonadotoxic effect of chemotherapy. However, similar to
the internationally observed practice [10], they were rarely
sent to a reproductive specialist. Before establishing ovarian
stimulation protocols adding tamoxifen and later aromatase
inhibitors [11] many oncologists considered conventional
ovarian stimulation protocols used for in vitro fertilization
treatments to be contraindicated due to hyperestrogenism, at
least in patients with hormone-sensitive breast cancer.
We defined two subgroups of patients for which pre-
servation of fertility might have come into consideration:
(a) The ‘‘classical’’ subgroup of patients who received
chemotherapy, i.e., a cytotoxic therapy with the
inherent hazard of fertility impairment or even
permanent loss of ovarian function.
(b) A second subgroup of patients who received an
adjuvant endocrine therapy only. To date, these
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patients have barely been considered when discussing
reproductive measures in young BC patients. Endo-
crine therapy does not lead to immediate damage of
ovarian tissue, but, since the recommended duration
of this therapy is 5 years, a BC patient might reach
her late reproductive years and face age-related
decline in fertility, if she follows the valid therapy
guidelines. In this case, preservation of fertility might
be appropriate prior to endocrine therapy to improve
the patient’s chances for having a child after therapy
completion.
Data collection methods and study design were
approved by the local Ethical Review Board.
Results
The data on patients’ age at diagnosis, disease stage, hor-
mone receptor status, therapy and outcome are summarized
in Table 1. In this particular subgroup of young BC
patients (defined as B40 years), 61 % were 36 years or
older at initial diagnosis. Fifty-eight patients (59.2 %)
received adjuvant chemotherapy and 40 patients (40.8 %)
had adjuvant endocrine therapy. Out of the 30 women
(30.6 %) who had no systemic therapy, one-third (n = 10)
refused the recommended adjuvant systemic therapy.
Forty percent of our cohort was childless at the time of
BC diagnosis. Nine percent had three or more children
(Table 2). The mean number of children in our study group
was 1.03 per woman. Five women gave birth to a child
after BC diagnosis and therapy (Table 2).
Potential candidates for fertility preservation (Table 3)
In order to assess how many BC patients were potential
candidates for FP at time of BC diagnosis, we developed an
algorithm using definitive exclusion criteria such as meta-
static disease at diagnosis (n = 2) and history of hyster-
ectomy (n = 2). Furthermore, 30 patients who did not
receive systemic therapy (n = 30) were not considered as
potential candidates for FP (some of these women might
have been potential candidates for various gynecological/
reproductive medicine reasons; our aim, however, was to
assess the number of patients who were candidates due to
BC-related therapy). The potential candidates for FP were
grouped according to the modality of tumor treatment.
Group A Fifty-six patients received adjuvant gonado-
toxic chemotherapy. Of these women, 20 patients (35.7 %)
were with the utmost probability, not candidates for FP
since their gynecological/obstetrical history was highly
suggestive of completed family planning (history of tubal
ligation or vasectomy of the partner, n = 6; patients who
had C three children, n = 4; women whose youngest child
was C8 years old, n = 10).
Thirty-six patients, i.e. 64.3 % of the patients treated
with chemotherapy, were identified as potential ‘‘classical’’
candidates for FP. The majority of them were childless at
diagnosis (n = 23, 63.9 %) and 19 women (52.8 %) were
in their late reproductive years, i.e. they were 36 years or
older at the time of BC diagnosis.
In order to assess how many of the potential candidates
for FP at the time of BC diagnosis might actually use their
cryopreserved gametes, we analyzed the situation of each
patient 5 years after BC diagnosis. Out of the 36 candi-
dates, eight patients (22.2 %) would not have been able to
use their cryopreserved gametes since they developed
distant metastases after a median time of 21 months (range
progression during adjuvant therapy—53 months). A fur-
ther six patients (16.7 %) were highly unlikely to use their
cryopreserved gametes because they chose to undergo
adnexectomy for hormone-ablative BC therapy in the fur-
ther course of disease.
The majority of the remaining 22 women who were
finally identified as potential candidates for using their
cryopreserved gametes were childless (n = 16, 72.7 %)
and in their late reproductive years, i.e. they were already
41–45 years old at the time of potentially using the cryo-
preserved gametes to achieve pregnancy (n = 12, 54.5 %).
Group B Out of ten patients who received endocrine
therapy only, five women had hypothetic exclusion criteria
for FP. From the remaining five patients, three women
were identified as potential candidates for using their
cryopreserved gametes 5 years after BC diagnosis.
Discussion
Women who face infertility due to oncological therapy have
few options to preserve their fertility before beginning can-
cer treatment [12]. Currently, the most common techniques
of FP are cryopreservation of embryos, oocytes and ovarian
tissue. Cryopreservation of embryos is an established
method, whereas cryopreservation of unfertilized oocytes
and ovarian tissue are still considered experimental, because
neither efficacy nor outcome has yet been established in large
numbers [7]. Ovarian tissue banking is considered for
younger women under the age of 35 years [13] who have no
time for an ovarian stimulation which usually needs about
2–3 weeks of time. It requires one laparoscopy to retrieve the
tissue and at least one other laparoscopy to autotransplant the
ovarian tissue orthotopically when the woman wants to get
pregnant. As of October 2011, we have knowledge of 17
children being born after autotransplanting cryopreserved
ovarian tissue [14]. Apart from requiring two invasive sur-
gical procedures, removing a whole or at least half an ovary
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will decrease the woman’s ovarian reserve in any case,
thus definitely lowering her chances for spontaneous
pregnancy and increasing her risk for premature meno-
pause [15].
The American Society of Clinical Oncology (ASCO)
and the American Society for Reproductive Medicine
(ASRM) have recommended that the impact of cancer
treatments on fertility should be addressed to all cancer
patients of reproductive age, and that options for FP, such
as embryo cryopreservation, should be discussed routinely
[7, 8]. We agree with these recommendations and strongly
support the approach that oncologists or oncological sur-
geons should routinely refer young BC patients to spe-
cialists for FP prior to treatment as early as possible. This
study aimed to assess the number of women in an unse-
lected cohort of young BC patients for whom such a con-
sultation on options for FP would go beyond the means of a
purely informational discussion and who actually might
choose the option of FP. This needs assessment might serve
as a basis for reproductive medicine centers planning FP
programs for cancer patients.
In order to assess how many BC patients are actually
candidates for FP, it is important to keep in mind that, even
in the cohort of young patients, the mean age is, at least
from the perspective of reproductive medicine, compara-
tively high. In our cohort, 61 % of the patients were at least
36 years old; in comparison, the cohort of lymphoma
patients who might be considered for FP is approximately
10–15 years younger [9]. This high percentage of women
in their late reproductive years has two important impli-
cations for the question issued in this study:
1. Many women have completed childbearing at the time
of BC diagnosis and the impact of oncologic therapy
on fertility is secondary.
Table 1 Age, disease stage, hormone receptor status, treatment and
outcome characteristics of young breast cancer patients
Entire cohort, number of patients 100
Age
Mean (range) 35.9 (26–40)
Age group: 26–30 years 10
Age group: 31–35 years 29








ER positive/PR negative 9







Systemic neoadjuvant/adjuvant therapy, n = 98b
No systemic therapy (%) 30 (30.6)
Chemotherapy alone (%) 28 (28.6)
Chemotherapy ? endocrine therapy (%) 30 (30.6)
Endocrine therapy alone (%) 10 (10.2)
Outcome
Alive, no evidence of breast cancer 57
Alive with metastatic breast cancer 9
Died of breast cancer 29
Died of other disease 2
Follow-up \3 months 3
ER estrogen receptor, PR progesteron receptor
a Stage classification according to the AJCC/UICC TNM Classifi-
cation, 7th edition. For 13 patients, who were treated with neoadju-
vant therapy, the tumor stage after surgery (ypTNM) was considered
b Exclusion of patients with stage IV disease at diagnosis (n = 2)
Table 2 Parity and reproductive outcome of young breast cancer







Mean number of children 1.03
Mean maternal age at birth of first child (range) 27.9 (17–37)
No. of pregnancy-associated BCa 6




Pregnancy after oocytes donation 1
Pregnancies after chemotherapyd 3
Average age at diagnosis of BC (range) 33 (30–39)
Average maternal age at birth of child (range) 38.6 (36–43)
Months between diagnosis and birth of child (range) 66.8 (14–117)
BC breast cancer
a Definition: breast cancer diagnosed during pregnancy or within 1 year
after giving birth
b Not considered: patients lost to follow-up after less than 3 months
(n = 3)
c Three pregnancies occurred after early discontinuation of endocrine
therapy with tamoxifen
d One pregnancy occurred after chemotherapy and during radiotherapy
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In our study, we gave special consideration to the family
structure (number and age of children) of our cohort and
hypothesized that women with more than three children
and women whose oldest child was already 8 years or older
have most likely completed childbearing and definitely
refrain from FP in the face of newly diagnosed BC.
Therefore, we excluded these patients as potential candi-
dates for FP as well as women who had a history of tubal
ligation or vasectomy of the partner, both highly suggestive
of completion of family planning. We are aware that these
factors are debatable but we are convinced that, out of the
women who meet our practice-orientated exclusion criteria,
only a clear minority will vote for FP, particularly in the
light of the next point.
2. The live birth rate after assisted reproductive technol-
ogy (ART) sharply declines with increasing maternal
age.
The live birth rate in ART using freshly collected
oocytes drops from 32.0 % at age 36 to 18.7 % at age 40
and to 2.9 % at age 44 [16]. ART cycles using frozen
gametes (as it would be the case after FP) show a decrease
in implantation rates as maternal age increases with an
implantation rate of 25 % in women less than 35 years and
an implantation rate of 18 % for embryos of women aged
38–40 years [16]. These data were collected from a healthy
population. To date, there is no evidence from controlled
trials on the live birth rate of BC cancer patients who
underwent FP. However, results from stimulation cycles
in oncologic patients suggest a disease-related poorer
response to ovarian stimulation [17]. We have to assume
that the aforementioned ART results are considerably
better than those that we can expect from cancer patients
undergoing FP in an emergency situation. These low suc-
cess rated could discourage patients from undergoing FP.
Some patients fear that a time-consuming fertility pre-
serving therapy might lead to a delay in treatment and that
ovarian stimulation might negatively impact the prognosis
of hormone-receptor positive BC [18]. Delay in treatment
of patients with BC can be avoided by prompt referral [12].
To date, controlled ovarian stimulation in combination
with aromatase inhibitors does not seem to have a negative
impact on recurrence rates [19].
BC-related FP comes only into consideration for
patients who receive a cytotoxic chemotherapy (the
‘‘classical’’ group for FP) or, up until now less common, for
patients who receive a long-lasting endocrine therapy. In
our cohort, however, 30 % of the patients did not receive
such a systemic therapy. Notably, a considerable number of
the patients who refused therapy did so with the explicit
wish still to have children. These patients made this deci-
sion fully conscious about the impact of their decision on
the outcome of a potentially life-threatening disease. Some
of these patients might have rejected systemic BC treat-
ment for financial reasons because health insurances in
Switzerland do not offer coverage for fertility preservation.
This clearly highlights the enormous pressure that many
young women face in this situation. The desire to achieve
pregnancy despite the presence of BC might not only result
in a non-compliance of therapy (i.e., not to start a recom-
mended therapy) but also in a high rate of non-persistence
to therapy. From the five patients who gave birth to a child
after BC therapy in our cohort, three women discontinued
ongoing endocrine therapy prematurely with the explicit
intention to get pregnant. A further four patients stopped
therapy for the same reason but pregnancy has not yet
occurred. Several studies demonstrated that non-compli-
ance and non-persistence was highest [20–23] in young BC
patients. It was assumed that these women might not have
adjusted to a diagnosis of BC as well as older women and
therefore were also less willing to accept or more likely to
experience therapy-related side effects [24, 25]. The wish
for childbearing, or at least to maintain fertility, seems to
be an additional factor that influences the decision not to
accept a recommended oncological therapy or to discon-
tinue therapy prematurely. Findings of a web-based survey
suggest that a large proportion of women—especially those
younger than 30 years—overestimate their risk of becom-
ing postmenopausal with BC therapy. This misperception
is worrisome in light of the fact that nearly one-third of
respondents indicated that fertility concerns impacted on
their treatment decisions [26]. Therefore, oncologists must
openly discuss fertility factors and a multidisciplinary
approach including reproductive specialists should be
attempted to provide the patients with adequate
information.
In our analysis, we identified approximately 35–40 %
(the first percentage includes patients who had chemo-
therapy; the latter percentage also includes patients who
had endocrine therapy only) of young BC patients as
potential candidates for FP. From the patients who received
chemotherapy, approximately 65 % were assessed to be
potential FP candidates. Notably, the majority of these
women were in their late reproductive years. Our hypo-
thetic analysis of the patients who were candidates for FP
showed that approximately 40 % of these patients no
longer were candidates for using their cryopreserved
gametes after 5 years, in the majority of the cases due to
the development of distant metastatic disease.
We consider that our quantitative approximation of
potential FP candidates based on retrospective data might
be a realistic assessment of the number of women afflicted
with BC aiming at FP. One might criticize that our cohort
includes a lead-time bias and included a too high number of
patients who did not receive systemic therapy (according
to therapy guidelines in the early 1990s; approximately
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two-thirds of the patients who did not have systemic
therapy had initial diagnosis between 1990 and 1995) and
that there might be a higher percentage of young BC
patients who will accept the recommended systemic ther-
apy in the future. This, and the fact that survival rates for
BC patients are increasing steadily, would lead to a higher
number of potential FP candidates. On the other side, we
did not consider personal motivation of the family struc-
tures of the patients of our cohort. In a group of young
childless women in their mid-thirties, there might be a
considerable percentage of women whose childlessness is
not a result of a yet unfulfilled wish for motherhood but a
conscious decision not to have children. For these women,
the offer of FP is not relevant. In our assessment, these
patients were not excluded from the number of potential FP
candidates. We feel that both factors would neutralize each
other enough that our assumed number of potential FP
candidates would still be a realistic assessment for the
future.
One major problem of FP preservation is the consider-
able time pressure on patients and their physicians [27]. It
would be essential to identify candidates for FP at an early
point so that patients are able to make their decisions both
on oncological therapy and FP [28, 29]. Information
transfer is challenging in this ethically and emotionally
complex situation [30] preferably with a fertility specialist
and at a time when the patient’s decision is likely to impact
outcome.
Biological parenthood is an important goal for most
cancer survivors and the experience of cancer might well
add to the appreciation of parenthood [5]. We think that
young women who had FP benefit emotionally from the
enhanced hope of future motherhood. On the other side, the
optimistic prospect of future parenthood must not detract
from the real hazards of BC. In our study cohort, 36 %
developed distant metastatic disease. From the 36 patients
who received chemotherapy and were identified as poten-
tial candidates for FP, six patients had early progression
within 2 years and three further patients developed distant
metastases in the further course of disease.
Our study demonstrates that in a cohort of young BC
patients only a minority of women are candidates for FP.
Young BC patients who wish to have children in the future
usually carry risk factors both from oncological and
reproductive medicine perspective. Due to this high-risk
profile, the rarity of BC in young age and the limited
number of patients who might actually chose FP, these
women must be offered timely and multidisciplinary
counseling in highly specialized centers. To improve our
knowledge and understanding of the challenging situation
of young BC patients with the wish to have children in the
future, the data of these patients must be collected in large
multicenter databases (such as FertiPROTECT, FertiSave).
Ongoing studies and those currently being designed will
‘‘study the different features contributing to the ‘‘puzzle’’
of safe and successful pregnancy after BC’’ [31].
Table 3 Potential candidates for fertility preservation at the time of
diagnosis (n = 100)
Exclusion criteria for fertility preservation 34
Disease-associated criteria: metastatic disease at diagnosis 2
Patient-associated criteria: history of hysterectomy 2
Patients who had no systemic adjuvant therapy 30
Potential candidates for fertility preservation
Group A (‘‘chemotherapy’’) 56
Hypothetic exclusion criteria for fertility preservation: 20
History of tubal ligation or vasectomy of the partner 6
Patient with 3 or more children 4
Youngest child C8 years 10
Remaining candidates for fertility preservation/thereof
nulliparous
36/23
Aged 26–30 years at diagnosis/thereof nulliparous 6/5
Aged 31–35 years at diagnosis/thereof nulliparous 11/6
Aged 36–40 years at diagnosis/thereof nulliparous 19/12
Potential candidates for fertility preservation and further
events during disease course
36
Developed metastatic disease within 2 years 6
Developed metastatic disease within 5 years 2
Underwent adnexectomy for hormone-ablative BC therapy 6
Lost to follow-up –
Potential candidates who might use fertility reserve/thereof
nulliparous
22/16
Aged 26–30 years at diagnosis/thereof nulliparous 3/3
Aged 31–35 years at diagnosis/thereof nulliparous 8/4
Aged 36–40 years at diagnosis/thereof nulliparous 12/9
Group B (‘‘endocrine therapy only’’) 10
Hypothetic exclusion criteria for fertility preservation: 5
History of tubal ligation or vasectomy of the partner 1
Patient with 3 or more children 2
Youngest child C8 years 2
Remaining candidates for fertility preservation/thereof
nulliparous
5/4
Aged 26–30 years at diagnosis/thereof nulliparous –
Aged 31–35 years at diagnosis/thereof nulliparous 4/4
Aged 36–40 years at diagnosis/thereof nulliparous 1/0
Potential candidates for fertility preservation and further
events during disease course
5
Developed metastatic disease within 2 years –
Developed metastatic disease within 5 years –
Underwent adnexectomy for hormone-ablative BC therapy 1
Lost to follow-up 1
Potential candidates who might use fertility reserve/there of
nulliparous
3/2
Aged 31–35 years at diagnosis/thereof nulliparous 2/2
Aged 36–40 years at diagnosis/thereof nulliparous 1/0
BC breast cancer
1526 Arch Gynecol Obstet (2012) 286:1521–1527
123
Conflict of interest The authors declare that there are no financial
or personal relationships with other people or organizations that could
inappropriately influence the work reported or the conclusions,
implications, or opinions stated.
References
1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012.
CA Cancer J Clin 62:10–29
2. Bland KI, Menck HR, Scott-Conner CE et al (1998) The National
Cancer Data Base 10-year survey of breast carcinoma treatment
at hospitals in the United States. Cancer 83:1262–1273
3. Martin J, Hamilton B, Ventura S et al. Births: Final data for 2009.
In National vital statistics reports. Hyattsville, MD: National
Center for Health Statistics 2011
4. Martinez GM, Chandra A, Abma JC et al (2002) Fertility, con-
traception, and fatherhood: data on men and women from cycle 6
of the 2002 National Survey of Family Growth. Vital Health Stat
23:1–142
5. Schover LR, Rybicki LA, Martin BA, Bringelsen KA (1999)
Having children after cancer. A pilot survey of survivors’ atti-
tudes and experiences. Cancer 86:697–709
6. Canada AL, Schover LR (2012) The psychosocial impact of
interrupted childbearing in long-term female cancer survivors.
Psychooncology 21:134–143
7. Ethics Committee of the American Society for Reproductive
Medicine (2005) Fertility preservation and reproduction in cancer
patients. Fertil Steril 83: 1622–1628
8. Lee SJ, Schover LR, Partridge AH et al (2006) American Society
of Clinical Oncology recommendations on fertility preservation
in cancer patients. J Clin Oncol 24:2917–2931
9. Lawrenz B, Jauckus J, Kupka MS et al (2011) Fertility preser-
vation in [1,000 patients: patient’s characteristics, spectrum,
efficacy and risks of applied preservation techniques. Arch
Gynecol Obstet 283:651–656
10. Forman EJ, Anders CK, Behera MA (2010) A nationwide survey
of oncologists regarding treatment-related infertility and fertility
preservation in female cancer patients. Fertil Steril 94:1652–1656
11. Oktay K, Buyuk E, Davis O et al (2003) Fertility preservation in
breast cancer patients: IVF and embryo cryopreservation after
ovarian stimulation with tamoxifen. Human Reprod 18:90–95
12. Sonmezer M, Oktay K (2006) Fertility preservation in young
women undergoing breast cancer therapy. Oncologist 11:422–434
13. von Wolff M, Donnez J, Hovatta O et al (2009) Cryopreservation
and autotransplantation of human ovarian tissue prior to cytotoxic
therapy–a technique in its infancy but already successful in fer-
tility preservation. Eur J Cancer 45:1547–1553
14. Dittrich R, Lotz L, Keck G et al (2012) Live birth after ovarian
tissue autotransplantation following overnight transportation
before cryopreservation. Fertil Steril 97:387–390
15. de Ziegler D, Streuli I, Vasilopoulos I et al (2010) Cancer and
fecundity issues mandate a multidisciplinary approach. Fertil
Steril 93:691–696
16. Centers for Disease Control and Prevention, American Society
for Reproductive Medicine, Society for Assisted Reproductive
Technology (2011) 2009 Assisted Reproductive Technology
Success Rates: National Summary and Fertility Clinic Reports.
Atlanta: US Department of Health and Human Services. Avail-
able at: http://www.cdc.gov/art/ART2009/PDF/ART_2009_Full.
pdf. Accessed 21 March, 2012
17. Friedler S, Koc O, Gidoni Y et al (2012) Ovarian response to
stimulation for fertility preservation in women with malignant
disease: a systematic review and meta-analysis. Fertil Steril 97:
125–133
18. Tschudin S, Bunting L, Abraham J et al (2010) Correlates of
fertility issues in an internet survey of cancer survivors. J Psy-
chosom Obstet Gynaecol 31:150–157
19. Azim A, Costantini-Ferrando M, Oktay K (2008) Safety of fer-
tility preservation by ovarian stimulation with letrozole and
gonadotropins in patients with breast cancer: a prospective con-
trolled study. J Clin Oncol 26:2630–2635
20. Barron TI, Connolly R, Bennett K et al (2007) Early discontin-
uation of tamoxifen: a lesson for oncologists. Cancer 109:
832–839
21. Guth U, Myrick ME, Kilic N et al (2012) Compliance and per-
sistence of endocrine adjuvant breast cancer therapy. Breast
Cancer Res Treat 131:491–499
22. Hershman DL, Kushi LH, Shao T et al (2010) Early discontin-
uation and nonadherence to adjuvant hormonal therapy in a
cohort of 8,769 early-stage breast cancer patients. J Clin Oncol
28:4120–4128
23. Partridge AH, LaFountain A, Mayer E et al (2008) Adherence to
initial adjuvant anastrozole therapy among women with early-
stage breast cancer. J Clin Oncol 26:556–562
24. Compas BE, Stoll MF, Thomsen AH et al (1999) Adjustment to
breast cancer: age-related differences in coping and emotional
distress. Breast Cancer Res Treat 54:195–203
25. Ganz PA, Schag CC, Heinrich RL (1985) The psychosocial
impact of cancer on the elderly: a comparison with younger
patients. J Am Geriatr Soc 33:429–435
26. Partridge AH, Gelber S, Peppercorn J et al (2004) Web-based
survey of fertility issues in young women with breast cancer.
J Clin Oncol 22:4174–4183
27. Kim J, Oktay K, Gracia C et al (2012) Which patients pursue
fertility preservation treatments? A multicenter analysis of the
predictors of fertility preservation in women with breast cancer.
Fertil Steril 97:671–676
28. Lee S, Ozkavukcu S, Heytens E et al (2010) Value of early
referral to fertility preservation in young women with breast
cancer. J Clin Oncol 28:4683–4686
29. Thewes B, Meiser B, Rickard J, Friedlander M (2003) The fer-
tility- and menopause-related information needs of younger
women with a diagnosis of breast cancer: a qualitative study.
Psychooncology 12:500–511
30. Tschudin S, Bitzer J (2009) Psychological aspects of fertility
preservation in men and women affected by cancer and other life-
threatening diseases. Hum Reprod Update 15:587–597
31. Pagani O, Partridge A, Korde L et al (2011) Pregnancy after
breast cancer: if you wish, ma’am. Breast Cancer Res Treat 129:
309–317
Arch Gynecol Obstet (2012) 286:1521–1527 1527
123
